statistiche ricercatore

Continente	#
NA - Nord America	626
EU - Europa	569
AS - Asia	312
SA - Sud America	48
Continente sconosciuto - Info sul continente non disponibili	31
AF - Africa	9
OC - Oceania	2
Totale	1.597

Nazione	#
US - Stati Uniti d'America	599
RU - Federazione Russa	145
IE - Irlanda	105
CN - Cina	86
SG - Singapore	85
DE - Germania	82
SE - Svezia	60
IT - Italia	50
HK - Hong Kong	45
VN - Vietnam	44
UA - Ucraina	38
BR - Brasile	34
IN - India	24
GB - Regno Unito	23
FR - Francia	21
FI - Finlandia	18
CA - Canada	17
AR - Argentina	10
PL - Polonia	6
EU - Europa	4
JP - Giappone	4
KR - Corea	4
MX - Messico	4
NL - Olanda	4
ZA - Sudafrica	4
BD - Bangladesh	3
EC - Ecuador	3
ES - Italia	3
IR - Iran	3
LT - Lituania	3
TR - Turchia	3
AU - Australia	2
BG - Bulgaria	2
DK - Danimarca	2
ID - Indonesia	2
JM - Giamaica	2
PK - Pakistan	2
AE - Emirati Arabi Uniti	1
AT - Austria	1
BE - Belgio	1
BS - Bahamas	1
CH - Svizzera	1
CL - Cile	1
CW - ???statistics.table.value.countryCode.CW???	1
DZ - Algeria	1
EG - Egitto	1
ET - Etiopia	1
GR - Grecia	1
GT - Guatemala	1
HR - Croazia	1
IL - Israele	1
KE - Kenya	1
KZ - Kazakistan	1
MD - Moldavia	1
OM - Oman	1
PA - Panama	1
PH - Filippine	1
PS - Palestinian Territory	1
PT - Portogallo	1
SA - Arabia Saudita	1
SN - Senegal	1
TT - Trinidad e Tobago	1
Totale	1.571

Nome	#
Alteration of BIRC3 and multiple other NF-kB pathway genes in splenic marginal zone lymphoma	162
CLINICAL IMPACT OF SMALL SUBCLONES HARBORING NOTCH1, SF3B1 OR BIRC3 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA	152
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up	141
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia	139
The genetics of nodal marginal zone lymphoma	138
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness	132
Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naïve patients with chronic lymphocytic leukemia	132
MOLECULAR BASIS OF TARGET THERAPY FOR AGGRESSIVE B-CELL LYMPHOMA	129
MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia	129
Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia	127
Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia	112
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia	104
Totale	1.597

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	75	0	0	0	10	7	0	6	1	10	7	14	20
2022/2023	215	12	11	22	0	11	14	7	14	109	0	10	5
2023/2024	79	8	7	5	3	14	1	13	2	0	1	2	23
2024/2025	152	2	1	2	3	9	13	17	10	31	17	8	39
2025/2026	587	31	28	32	86	56	39	78	119	43	55	15	5
2026/2027	131	16	39	31	45	0	0	0	0	0	0	0	0
Totale													1.597